# GKCC

> GKCC is a VC fund in Wilmington backing Biotechnology, Medical and Health Care. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Wilmington, United States
- Total investments: 8
- Last investment: Jun 2026
- Lead investor: 50%
- Last updated: Aug 2026

GKCC is a VC fund in Wilmington focused on Biotechnology and Medical. GKCC operates as an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 75% |
| Medical | 4 | 50% |
| Health Care | 4 | 50% |
| Medical Device | 2 | 25% |
| Pharmaceutical | 2 | 25% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 25% |
| Seed | 1 | 13% |
| Series B | 1 | 13% |
| Post-IPO Debt | 1 | 13% |
| Post-IPO Equity | 1 | 13% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 63% |
| Canada | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| xCures | The convergence of genomics, precision medicine, and AI have created an unprecedented moment in the world of oncology. But the drug-centric way in which treatments are developed and the haphazard way in which knowledge about those treatments is captured and delivered to the point of care does not serve patients well. xCures is changing that, withan AI-based precision oncology platform that tightly integrates cancer research and care.The xCures platform runs a perpetual trial that captures Real World Evidence (RWE) to continuously learn from all patients, on all treatments, all the time. It coordinates treatment recommendations across all patients and institutions to match patients with the treatments that work. And it packages RWE for use by stakeholders across oncology, slashing the time and cost of drug development and saving lives. | $46M | Series B | Jun 24, 2026 |  |
| Elicio Therapeutics | Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses. | $10M | Post-IPO Equity | Jan 30, 2025 |  |
| Esphera SynBio | Esphera SynBio operates as a biotechnology company. Esphera SynBio provides practitioners of synthetic biology for the treatment and prevention of disease. | $2M | Seed | Jan 07, 2025 |  |
| Tracer Biotechnologies | Tracer Biotechnologies is a biotechnology company that offers monitoring services for oncology patients. | $10M | Series A | Dec 12, 2024 |  |
| Elicio Therapeutics | Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses. | $20M | Post-IPO Debt | Aug 12, 2024 |  |
| RareCyte | RareCyte is a provider of precision biology solutions that delivers platforms and services in both spatial biology and liquid biopsy. It offers tissue-based imaging tools under the Orion Spatial Biology suite, including imaging instruments and panels enabling multiplexed biomarker analysis in a single scan, and supplies rare cell analysisinstruments and consumables such as the CyteFinder II imaging systems, CytePicker module, AccuCyte sample preparation, and RarePlex panel kits for circulating tumor cell (CTC) detection and characterization. Additionally, RareCyte extends its offering with precision biology services encompassing custom assay development, clinical trial sample testing, and data analysis. | $20M | Venture - Series Unknown | Jun 27, 2024 |  |
| Elicio Therapeutics | Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses. | $7M | Post-IPO Equity | Dec 22, 2023 |  |
| Actym Therapeutics, Inc. | Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies,STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy.In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures. | $25.5M | Series A | Oct 18, 2023 |  |

8 of 8 investments shown.

## Co-investors
- [Panacea Venture](https://shizune.co/investors/profile/panacea-venture) — VC Fund, 2 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 1 deal together
- [Agilent Technologies](https://shizune.co/investors/profile/agilent) — VC Fund, 1 deal together
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 1 deal together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 1 deal together
- [Caffeinated Capital](https://shizune.co/investors/profile/caffeinated-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does GKCC invest in?

GKCC invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did GKCC last invest?

The most recent investment recorded for GKCC closed in Jun 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co